C3 and Fabry disease: Importantly, C3a concentrations above 5000 ng/mL were observed in all treatment-naive patients with Fabry disease, and this elevated level persisted even after enzyme replacement therapy, particularly in individuals with marked reduction in Lyso-Gb3 and positivity for drug specific IgG antibodies (Drug-IgG) [21].